Cellectis/CLLS

$2.61

-2.97%
-
1D1W1MYTD1YMAX

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Ticker

CLLS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andre Choulika

Employees

236

Headquarters

Paris, France

Cellectis Metrics

BasicAdvanced
$193.9M
Market cap
-
P/E ratio
-$2.21
EPS
3.09
Beta
-
Dividend rate
$193.9M
3.08552
$3.77
$0.96
37.75K
2.717
59.709
66.902
-5.89%
-32.81%
-59.52%
-40.55%
7.609
1.315
1.716
76.59%
12.34%
3.82%

What the Analysts think about Cellectis

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
184.67% upside
High $11.00
Low $3.00
$2.61
Current price
$7.43
Average price target

Cellectis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-857.14% profit margin
QuarterlyAnnual
Q1 23
QoQ growth
Revenue
$3.5M
-81.68%
Net income
$-30M
-45.65%
Profit margin
-857.14%
196.59%

Cellectis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.43%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.59
-$0.58
-$0.19
-$0.31
-
Expected
-$0.71
-$0.48
-$0.45
-$0.42
-$0.22
Surprise
-16.9%
20.37%
-58.18%
-25.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Cellectis stock?

Cellectis (CLLS) has a market cap of $193.9M as of April 16, 2024.

What is the P/E ratio for Cellectis stock?

The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of April 16, 2024.

Does Cellectis stock pay dividends?

No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Cellectis dividend payment date?

Cellectis (CLLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Cellectis?

Cellectis (CLLS) has a beta rating of 3.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cellectis stock price target?

The target price for Cellectis (CLLS) stock is $7.43, which is 184.67% above the current price of $2.61. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cellectis stock

Buy or sell Cellectis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing